Pharmaceutical News

RSS

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

Allergy immunotherapy, generally referred to as allergy vaccinations or shots, reduce total health care costs in children with allergic rhinitis (hay fever) by one-third, and prescription costs by 16 percent, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).

11 Jan 2010

Los Angeles International Airport offers H1N1 flu shots in airline terminals

Los Angeles International Airport (LAX), in partnership with FLU*Ease, Inc., is now offering flu shots to travelers in most of the airline terminals as a public safety measure against the flu, especially the H1N1 strain.)

11 Jan 2010

Targacept signs collaboration and license agreement with AstraZeneca

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that its collaboration and license agreement with AstraZeneca for the global development and commercialization of TC-5214 for major depressive disorder (MDD) has become effective as a result of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

11 Jan 2010

Wall Street Journal examines polio vaccinations in Afghanistan

In a story about polio vaccination campaigns in Afghanistan, the Wall Street Journal examines how the Taliban and international health agencies are working together to promote oral vaccination campaigns across the country.

11 Jan 2010

Galderma S.A. offers $3.75 million to NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a new class of anti-infectives for treating multi-drug resistant pathogens, announced today that it has received $3.75 million in milestone payments from partner Galderma S.A.

11 Jan 2010

Lives of 400 Swedes can be saved annually if side effects of pharmaceuticals prevented

A scientific study indicates that the lives of 400 Swedes could be saved annually if measures were taken to prevent side effects of pharmaceuticals. Now these researchers in Sweden, at the Nordic School of Public Health (NHV) and elsewhere, have reviewed randomly selected deaths in three Swedish counties and found that 14 percent of these deaths could have been avoided if a drug had been replaced or if the dosage had been lowered.

11 Jan 2010

Meda receives exclusive rights to distribute AML drug in Europe and Asia

Meda has in-licensed exclusive rights to Ceplene (histamine dihydrochloride) from EpiCept Corporation, a US-based biopharmaceutical company.

11 Jan 2010

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

EpiCept Corporation announced today that it has entered into an exclusive commercialization agreement for Ceplene® (histamine dihydrochloride) with Meda AB, a leading international specialty pharmaceutical company based in Stockholm. Ceplene is EpiCept’s novel therapy approved in the European Union with orphan drug status for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.

11 Jan 2010

Bryant Ranch Prepack tracks medications from its manufacture to the patient with E Pedigree

“More and more physicians are realizing that prescriptions that leave the office are like money walking out of the door,” said Fred Ganjian, Vice President of Sales and Marketing for Bryant Ranch Prepack, a leading supplier of prepackaged physician-dispensed prescription programs. “In this day of continuing pressure on physicians to cover their costs, physician-dispensed prescriptions have become increasingly important to a physician’s bottom line,” he added.

11 Jan 2010

Highmark joins with CDC to promote National Influenza Vaccination Week

Beginning Sunday, Jan. 10 and continuing through the week, Highmark Inc. will join with the Centers for Disease Control (CDC) to promote National Influenza Vaccination Week.

10 Jan 2010

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

AMAG Pharmaceuticals, Inc. today provided an update on the commercial launch of Feraheme® (ferumoxytol) Injection for intravenous (IV) use, including preliminary fourth quarter 2009 Feraheme net product revenues estimates, as well as an update on the Company’s international and label expansion efforts.

10 Jan 2010

Thirteen percent of poison exposure calls related to painkillers

U.S. poison centers answered more than 4.3 million calls in 2008, including nearly 2.5 million calls about human exposures to poison, according to the American Association of Poison Control Centers -- up from 4.2 million calls in 2007.

9 Jan 2010

Selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference

“This year’s BIO CEO & Investor Conference will provide a unique forum to showcase therapeutic areas with key catalysts – from new and dynamic therapies to cutting edge investment opportunities,” said Alan Eisenberg, executive vice president of Emerging Companies & Business Development at BIO.

9 Jan 2010

Americans encouraged to get H1N1 flu vaccine during National Influenza Vaccination Week

The U.S. Department of Health and Human Services (HHS) and its Centers for Disease Control and Prevention (CDC) announced a nationwide effort to encourage more Americans to get the H1N1 flu vaccine during National Influenza Vaccination Week, January 10–16, 2010.

9 Jan 2010

Results of randomized, placebo-controlled study of Ambrotose complex announced

Mannatech, Incorporated, a global pioneer in the development of high-quality health, weight and fitness, and skin care solutions based on nutritional science, announced the results of a randomized, double-blind, placebo-controlled study that shows healthy middle-aged adults who took one teaspoon of Ambrotose® complex twice daily performed significantly better on memory tasks and were overall more positive in their mood.

9 Jan 2010

Illicit drug use among older adults may lead to increase in substance abuse treatment services

A new study done by the Substance Abuse and Mental Health Services Administration (SAMHSA) indicates that the aging of the baby boom generation is resulting in a dramatic increase in levels of illicit drug use among adults 50 and older. These increases may require the doubling of substance abuse treatment services needed for this population by 2020, according to the report.

9 Jan 2010

Recent releases in Global Health

A Lancet Comment examines the "grossly insufficient" progress towards meeting the Millennium Development Goal (MDG) of reducing under-5 child mortality. "Accelerated progress can be achieved, even in the poorest environments, through: integrated, evidence-driven, and community-based programmes that focus on addressing the major causes of death, including pneumonia, diarrhoea, newborn disorders, malaria, HIV, and undernutrition; reaching the unreached with a basic package of interventions at large scale and achieving coverage with equity; and using data for action and advocacy," the comment concludes (You et al., 1/9).

9 Jan 2010

AIIRA/CCB drug combination provides superior safety and efficacy compared to other fixed-dose combinations

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a hypertension drug that requires less-frequent dosing than Novartis's Diovan/Tareg (valsartan) would earn 30 percent patient share according to surveyed U.S. cardiologists

9 Jan 2010

FDA yet to review MannKind’s NDA for insulin therapy

MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind’s new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.

9 Jan 2010

Green Cross seeks regulatory approval for peramivir in S.Korea

BioCryst Pharmaceuticals, Inc. today announced that it has been informed by its partner, Green Cross Corp., that Green Cross has filed a New Drug Application (NDA) in South Korea to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza.

9 Jan 2010

Pharmaceutical News

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

Los Angeles International Airport offers H1N1 flu shots in airline terminals

Targacept signs collaboration and license agreement with AstraZeneca

Wall Street Journal examines polio vaccinations in Afghanistan

Galderma S.A. offers $3.75 million to NovaBay Pharmaceuticals

Lives of 400 Swedes can be saved annually if side effects of pharmaceuticals prevented

Meda receives exclusive rights to distribute AML drug in Europe and Asia

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

Bryant Ranch Prepack tracks medications from its manufacture to the patient with E Pedigree

Highmark joins with CDC to promote National Influenza Vaccination Week

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

Thirteen percent of poison exposure calls related to painkillers

Selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference

Americans encouraged to get H1N1 flu vaccine during National Influenza Vaccination Week

Results of randomized, placebo-controlled study of Ambrotose complex announced

Illicit drug use among older adults may lead to increase in substance abuse treatment services

Recent releases in Global Health

AIIRA/CCB drug combination provides superior safety and efficacy compared to other fixed-dose combinations

FDA yet to review MannKind’s NDA for insulin therapy

Green Cross seeks regulatory approval for peramivir in S.Korea

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News